

Sebastian Kreiter to present on pioneering RNA immunology for cancer vaccines at Cancer Vaccines 2015

Author and leading scientist from BioNtech RNA talks to SMi about latest developments in RNA vaccinology & his upcoming presentation in an exclusive interview.

LONDON, ENGLAND, UNITED KINGDOM, June 19, 2015 /EINPresswire.com/ -- SMi Group's 4th annual [Cancer Vaccines conference](#) will lay out an agenda this autumn aimed to empower researchers with the knowledge to develop the next generation of cancer therapeutics. A presentation by the VP of Immunotherapy at BioNTech RNA, Dr Sebastian Kreiter, will be just one of the highlights at the 4th annual show this autumn.

Dr Kreiter recently took part in the pioneering development of actively personalized cancer vaccination where he worked out the scientific and technical PoC for an mRNA based mutanome vaccine in murine model systems together with team members.

His presentation entitled: RNA - Vaccinology: From Ware-Houses to Actively Personalized Cancer Vaccines, will discuss simulating tumour-specific antigen recognition with a focus on epitope design of multi-antigen tumour vaccines and neo-antigens.

When asked who how accessible fully - personalised cancer treatments would become, he said:

“We use an individually tailored synthetic RNA vaccine for inducing immune responses against multiple mutations thereby enabling the patient’s immune system to specifically recognize and attack the cancer cells (“MERIT”: Mutanome Engineered RNA Immuno-Therapy). Conceptually this therapy is suitable for all cancer indications and we are aiming to develop it as universal “just in time” medicine. Our objective is to make our approach of truly personalized cancer immunotherapies available for a broad range of patients and at an affordable rate.”

On what attendees will take away from his talk, he commented:

I will give insight into the main accomplishments of our mRNA vaccine platform demonstrated in pre-clinical studies showing its great potential as cancer vaccine. Furthermore I will present the concept of MERIT (Mutanome Engineered RNA Immuno-Therapy) and show the preclinical PoC work. Finally I will present first results from our early clinical trials (MERIT, warehouse).

The full interview is available to read in the conference [download centre](#).



Other key speakers at Cancer Vaccines 2015 will include Kings College London, Vaccinogen, GSK, Roche and the National Cancer Institute.

To download a brochure visit the [website](#)

Cancer Vaccines 2015

16 - 17 Sept 2015

Marriott Regents Park, London, UK

www.cancervaccinesevent.com/ein

Lead sponsor: Northwest Biotherapeutics

---end---

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Teri Arri

SMi Group Ltd

+442078276162

[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.